Neuropace, Inc. (NPCE)
NASDAQ:NPCE
Earnings Data
Report Date
May 07, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.22Last Year’s EPS
-0.21Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong commercial execution and material clinical and product progress: robust revenue growth (Q4 +24%, FY +25%), sustained RNS momentum, margin expansion, positive adjusted EBITDA and cash generation in Q4, and meaningful regulatory and AI product milestones (IGE PMA acceptance; Seizure ID submission). Offsetting items include an expected near-term adjusted EBITDA loss for 2026 (‑$9M to ‑$10M) due to front-loaded commercial investments and seasonality, the wind-down of the DIXI partnership, and the need for payer coverage work before any IGE approval translates into revenue. Overall, the positives around growth, margins, product/clinical milestones and disciplined operating leverage significantly outweigh the manageable near-term headwinds and investment-driven profitability pressure.Company Guidance
Strong Top-Line Growth
Total revenue of $26.6M in Q4 2025, up 24% year-over-year; full year 2025 revenue of $100M, up 25% versus 2024.
RNS System Momentum
RNS System revenue of $22.4M in Q4 2025, up 26% year-over-year; RNS grew 25% for the full year 2025. RNS growth in H2 2025 was 29%, with the majority of growth driven by Level 4 centers.
Improved Gross Margins
Company gross margin >77% (77.4% in Q4 2025 vs 75.4% in Q4 2024, roughly +200 bps year-over-year). RNS gross margin >80% (80.5% in Q4 2025; full year RNS gross margin 81.9%).
Positive Adjusted EBITDA and Cash Generation
Second consecutive quarter of positive adjusted EBITDA at $0.9M in Q4 2025 (improvement of $1.9M YoY). Positive operating cash flow of ≈$0.5M and free cash flow of ≈$0.4M in Q4. Cash, cash equivalents and short-term investments totaled $61.1M, up $1.1M from the prior quarter.
Regulatory and Clinical Milestone — IGE Submission Accepted
PMA supplement for idiopathic generalized epilepsy (IGE) submitted Dec 15 and accepted by FDA to initiate the 180-day review. NAUTILUS 18-month results show a 77% median seizure rate reduction with favorable safety in a highly refractory population.
Product and AI Pipeline Progress
Seizure ID (AI-enabled seizure detection) submitted and expected approval in H1 2026; clinician platform moving to cloud. Progress on remote programming, a NeuroPace foundation model leveraging >24M iEEG recordings and continued next-generation platform development.
Reiterated 2026 Revenue Guidance and Focused Commercial Investment
Reiterated full year 2026 revenue guidance of $98M–$100M (implying underlying RNS growth of 20%–22%). Planned investments include targeted sales headcount, incentive updates and expanded nurse navigator resources to improve funnel conversion and access.
Operating Leverage Demonstrated
Q4 operating expense growth of 13% versus revenue growth of 24%, and normalized full year operating expense growth of ~13% versus revenue growth of 25%, indicating improved leverage as the business scales.
NPCE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NPCE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 03, 2026 | $13.83 | $13.95 | +0.87% |
Nov 04, 2025 | $9.40 | $12.98 | +38.09% |
Aug 12, 2025 | $9.13 | $9.32 | +2.08% |
May 13, 2025 | $12.95 | $15.60 | +20.46% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Neuropace, Inc. (NPCE) report earnings?
Neuropace, Inc. (NPCE) is schdueled to report earning on May 07, 2026, After Close (Confirmed).
What is Neuropace, Inc. (NPCE) earnings time?
Neuropace, Inc. (NPCE) earnings time is at May 07, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NPCE EPS forecast?
NPCE EPS forecast for the fiscal quarter 2026 (Q1) is -0.22.